My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.830 -0.170 (-5.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Chief Financial Officer Transition
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.